# Recruitment to Cancer Clinical Trials: Challenges and Strategies

Elizabeth Ness, MS, BSN, RN, CRN-BC™ Director, Office of Education and Compliance



1

#### Introduction

- Validity of clinical research studies are dependent on:
- Recruitment of adequate numbers of a required participant population
- Retaining participants
- Ensuring the protocol is followed
- Inefficient recruitment may have scientific, economic, and ethical consequences

NIH) NATIONAL CANCER INSTITUTE

3

#### The Issue

- 86% of all clinical trials fail to finish on time
- 60% of clinical trials are delayed or terminated due to lack of enrollment
- 19% of clinical trials terminate early
- 20% delayed 6 months or longer
- Hard to reach populations
- Traditional methods of recruitment are costly with low participation rates

Huang et al, 2018

**Disclosure for Participants** 

- Criteria for Successful Completion:
  - ✓ Attendance at 80% of the session and submission of an evaluation form
- No one with the ability to control content of this activity has a relevant financial relationship to disclose with an ineligible company
- National Cancer Institute is approved as a provider of nursing continuing professional development by the Ohio Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. (OBN-001-091). The approved provider unit activity number is 2022005

#### **Impact of Poor Accrual**

- Hinders the progress of research
- Demonstrates poor stewardship of our most valuable resource, study participants
- Leads to early closure which exposes participants to risk for potentially no benefit
- Lack of dissemination
- Financial impact of maintaining open trials that are not enrolling

NIH) NATIONAL CANCER INSTITU

4

# Recruitment in Cancer Clinical Trials (CTTs)

- Estimated 20% of adult cancer patients are eligible for a clinical trial
- 15-25% of eligible patients participate in a clinical trial
- Only 2-8% of cancer patients in U.S. participate in a cancer clinical trial
- 25% of CCTs fail to enroll enough patients
- 18% closed with less than 50% of the targeted sample size
- 40% of CCTs sponsored by NCI never reach completion and publication
- Participation decreases with age
- Ethnic and minority groups are underrepresented

NATIONAL CANCER INSTITUTE

Morain & Largent, 2019; Cartmell et al, 2020; Unger et al, 2021

5

# Barriers to Participation Clinician System Patient

#### **Clinician Centered Barriers**

- Impact on doctor-patient relationshipLosing trust
- Concern for patients
- Patients will be unable to comply
- Lack of interest in the specific research question
- Fear of not being kept informed about patient's care

NIH) NATIONAL CANCER INSTI

0

#### **System Barriers**

- Institutional
- NIH IRP research only
- Protocol Issues
- Eligibility
- Procedures
- Expense
- Competition
- Sponsor-centered
- Adequate funding
- Site selection
- Investigator selection

NATIONAL CANCER INSTITU

9

## **General Population Barriers**

- Lack of Awareness
- Mistrust
- Misperceptions
- Portrayal as guinea pig
- Comfort level with physician
- Demands of the study
- Preference for a particular treatment
- Health literacy
- Concerns about side effects
- Loss of privacy
- Geographical limitations
- Financial

10

# Barriers to Recruiting Underserved/Underrepresented...

- Lack of awareness of clinical trials
- Lack of awareness of benefits to participation
- Distrust of doctors
- · Different values or beliefs
- · Lack of cultural sensitivity
- · Language or literacy barriers

Underserved/underrepresented: older adults, racial/ethnic minorities, sexual/gender minorities, adolescents and young adults, patients with well-managed comorbidities


NH) NATIONAL CANCER INSTITU

# ... Barriers to Recruiting Underserved/Underrepresented

- Employment obligations
- Comorbid conditions
- Presentation at late stage of disease
- Limited transportation
- Sense that participants don't get anything from participation
- Lack of minority Principal Investigators

NH) NATIONAL CANCER INSTITU

12



Older Adults (≥ age 70) & CCTs 42% of overall cancer population FDA registered trials average enrollment is 24% Provider Patient System Caregiver Eligibility Concern for Knowledge Preferences toxicity criteria Concern for Consent form Burden Transportation language patient age Time/burden Time/burden Trial availability Preference for Concerns about another efficacy and treatment toxicity Finances Sedrak et al, 2020

#### **Good News!**

94-96% participants said that they would participate in a clinical trial again

https://www.ciscrp.org/wp-content/uploads/2020/01/The-majority-ofvolunteers-would-participate-in-a-clinical-trial-study-again.png

**STRATEGIES** 

16

14

15

# **Recruitment Strategies** Potential subjects contact investigators about Passive participating in research Potential subjects are identified by investigators Active and contacted about participating in a study

**Stating the Obvious** • Identify and remove barriers Assess barriers to clinical trial participation Identify actions to remove barriers Prioritize actions Introduce clinical research/clinical trials earlier within the patient experience

17 18

#### Recruitment Plan...

- Outlined in the protocol and approved by the IRB
- Occurs during protocol development process and throughout active accrual
- How will potential participants be initially identified for this study? Who will identify them?
- How and when will potential participants be approached/contacted about study participation?
- Who will conduct these activities and where will they occur?
- Activities that can be done w/o consent

NATIONAL CANCER INSTITU

19

#### ...Recruitment Plan...

- If recruitment plan involves contacting an individual multiple times to secure their initial enrollment in the study, describe how frequently and in what manner individuals will be contacted.
- Identify all recruitment methods that will be used.
   If recruitment plan involves using any email, address and/or telephone lists, how will those lists be obtained?
- Describe any provisions to protect the privacy and/or confidentiality of potential participants.

20

#### ...Recruitment Plan

- Will screening procedures be used? If so, who will conduct the screening procedures?
- Will there be collection of any information/data from potential participants during the recruitment and/or screening process?
- How will it be collected (i.e., what procedures will be used)?
- Identify all data points that will be collected prior to their enrollment in the study.

NIH) NATIONAL CANCER INSTITUT


21

## **Recruitment Strategies**

- Describe how participants will be identified, note efforts to include under-represented minorities.
- [Include for all trials posted on clinicaltrials.gov]
   This study will be posted on NIH websites [add for treatment trials] and on NIH social media forums.
- Add any other ways you will advertise the study as well as how potential subjects might be selected to be contacted or referred to you. These can include referrals from physicians, drawing from populations in NIH Clinics, etc. Recruitment advertisements and letters must be submitted to the IRB

22

NIH) NATIONAL CANCER INSTITUT



ResearchMatch

JOHN NOW ALLOUT RESEARCHERS NETWORK TRALLS RESULTS CONTACT US LOGIN

AND TRANSPORT TRALLS RESULTS CONTACT US LOGIN

AND TIPOTON TRANSPORT TRALLS RESULTS CONTACT US LOGIN

AND TIPOTON TRANSPORT TRALLS RESULTS CONTACT US LOGIN

AND TIPOTON TRANSPORT TRALLS RESULTS CONTACT US LOGIN

EN Expandor

EN Expandor

TOTAL RESEARCHERS DISTRICTIONS


Make a positive impact by volunteering in research.

John Today

Medical discoveries are not possible without volunteers like you.

ResearchMatch is a nonprofit program funded by the National institutes of Health (NHs). It helps to connect people interested in researchers from top, medical centers across the U.S.

https://www.researchmatch.org/



#### **Leveraging Technology**

- Use of EMR/EHR to trigger an alert if a patient is likely eligible for an ongoing clinical trial
- Clinical trial management software

NIH) NATIONAL CANCER INSTITU

25

26

#### **Protocol**

- What makes this protocol exciting/important?
- What type of competition is out there?
- Why would a patient enroll in this study?
- Why would a patient not want to enroll in this study?
- Why would a physician be reluctant to refer a patient to this study?

NIH) NATIONAL CANCER INSTITU

27

## **Study Population**

- Know your catchment area
- Demographics
- Cancer risk factors
- Cancer rates
- Study population should be appropriate for the research question being asked
- Involve members of the study population in planning efforts when possible

NIH) NATIONAL CANCER INSTITU

28

## **Broadening Eligibility Criteria...**

- 2016: American Society of Clinical Oncology (ASCO) and Friends of Cancer Research began a joint project to evaluate current eligibility criteria and determine how to broaden the criteria
- FDA published guidances:
- Brain Metastases
- HIV/AIDS
- Organ Dysfunction and Prior and Concurrent Malignancies
- Minimum Age for Enrollment

NATIONAL CANCER INSTITUT

## ... Broadening Eligibility Criteria

- February 2021 additional recommendations published to broaden criteria related to:
- Washout periods and concomitant meds
- Performance status
- Laboratory test intervals and reference ranges
- Prior therapies

#### UPCOMING JOURNAL CLUB

March 16th 1PM -2PM

Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement

NIH) NATIONAL CANCER INSTITUTE

29

## Underserved/Underrepresented...

- Enhance credibility of study by using a community spokesperson/lay outreach workers
- Getting the word out (e.g., Community events; Health Fairs; Workshops)
- Invest in community education and outreach programs
- Speak the language of the community
- Provide culture and language-appropriate informational materials

31

#### ...Underserved/Underrepresented

- Reach out to key decision makers in targeted groups
- Leverage satellite sites to conduct clinical trials
- Involve minority researchers/physicians
- Staff/researcher education
  - Recruitment and retention of minority populations
- Cultural awareness/sensitivity
- Bias

32

Navigator...

- Member of the healthcare team who helps patients "navigate" the healthcare systems
- Help patients understand the healthcare system
- Connect patients with resources
- Enhance patient-clinician communication
- Identify barriers and facilitate strategies to eliminate the barriers on an individual basis
- Increase patient clinical trial access. awareness, and knowledge as well as appropriately match trials for patients

33

Nipp et al. 2019; Cartmell et al. 2020

...Navigator

- Provide input on study design and recruitment for underserved/underrepresented populations
- Include a culturally competent navigator as a member of the clinical trial team to promote patient participation
- Patient navigators
  - Nurse navigators
  - Lay navigators

Nipp et al. 2019: Cartmell et al. 2020

34

#### **Promising Research With Social** Media as a Recruitment Tool

- HIV vaccine clinical trials (2009 YouTube, Wikipedia, Facebook, Craigslist)
- Occipital nerve studies (2013)
- Pediatric cancer (2015 Facebook)
- Depression prevention (2013)
- Smoking cessation (2013 Google AdWords, WebMD.com, Facebook, Twitter; 2014 - Facebook)
- Hard to reach populations:
- Young cancer survivors (2014 online newspapers, Craigslist, university website, email to advocacy groups, Facebook, Twitter)
- Gay Latino males (2014 Facebook, Craigslist, smartphone apps [Grindr, SCRUFF, Jack'd])
- Deaf community(2013 project website)

Gelinas, 2018

communication Easy updating

Wider audience

Low cost (?)

Instantaneous

Social Media

**Advantages** 

- Interactive
- Self-education

**Disadvantages** 

- Information chaos!
- Misinformation abounds
- Communication "too easy"-just a click
- Lack of patient/physician boundaries
- "Private" information becomes "public"
- Self-selection bias

Topolovec-Vranic et al. 2016

36

#### But.....

- Lack of regulatory guidance
- Informed consent process begins with recruitment
- IRB review of recruitment materials
- PI should be able to recruit the required number of participants in a specified timeframe
- Few resources

NET NATIONAL CANCER INS

37

#### **Ethical Principles Applied to Participant Recruitment** Respect for · Accurate information to assure the potential Persons participant can make an informed, and voluntary decision to enroll and withdraw, without coercion or inappropriate inducement Accurate and full disclosure of anticipated benefits (if any) and a disclosure of the possible risks of the study Beneficence Recruitment process should ultimately describe all the steps to maximize the study's benefit (if any) and minimize or avoid undue risk(s). Justice Study should be seen by the participant as fair in that it's open to all those in the cohort who could possibly benefit from the study. The risks and benefits are interpreted by the participant as equitably distributed.

38

# Things to Consider When Using Social Media...

- Online recruitment materials should follow the same guidelines applicable to traditional recruitment methods
- Recruitment materials must be reviewed and approved by the IRB
- Investigator contact information, information about the purpose of the study, any eligibility criteria, benefits to the subject, and time commitment required for participation in the study
- No promise free medical treatment, imply unanticipated benefits, or emphasize payment

NIH) NATIONAL CANCER INSTITUTI

39

# ...Things to Consider When Using Social Media...

- Potential participants interested in the study should be directed to contact the study team via non-public means
- Research teams need to:
- be familiar with the terms and conditions of any sites used for recruitment to ensure potential participants are not asked to violate a service agreement
- consider informing participants that they should be aware of the terms and conditions of the website to understand what, if any, data may be used/maintained by the website itself
- consider how the target population uses social media

40

# ...Things to Consider When Using Social Media

- Inform participants of third-party risk of interception when transmitting data and data back-up processes
  - "Your confidentiality will be kept to the degree permitted by the technology being used. No guarantees can be made regarding the interception of data sent via the Internet by any third parties."
  - "Data may exist on backups or server logs beyond the time frame of this research project."

NIH) NATIONAL CANCER INSTITU

#### Social Media Resource

- Harvard Catalyst Regulatory Foundations, Ethics, & Law Program. The Use of Social Media in Recruitment to Research: A Guide for Investigators and IRBs.
  - Investigator checklist
  - IRB checklist
  - https://catalyst.harvard.edu/pdf/regulatory/Social Media Guidance.pdf

NIH) NATIONAL CANCER INSTITUT

# **Precautions with SM and CTs at NIH**

- NIH IRP <u>Guidance Regarding Social Media</u> Tools
- Lists questions to be considered by investigators

NIH) NATIONAL CANCER INSTITU

43

## **Apps**

- Examples:
  - University specific (e.g., Univ of Kansas CC)
  - Pharma (e.g., Roche's Clinical Trial Match)
  - Clinical Trials App
  - Journal Club: Medicine
  - CUREITT
  - FDA's MyStudies (open source)
- Risk of therapeutic misbranding
- Needs IRB approval
- Similar considerations as with social media
- "Pay to play"

Morain & Largent, 2019

# **Retention Strategies**

- Ongoing informed consent
- Effective communication with the research participant
- Thank you cards
- Share study results
- Discuss the need for ongoing contact information to ensure accurate phone numbers, address and emergency contacts.
- Engaging the participant's family/significant other and established/referring providers
- Lost to follow up

45

#### Summary

44

- Advances in cancer treatment require efficient clinical trial processes especially focused on recruitment
- Recruitment can impact the ability to answer research questions
- Assess local/regional barriers to recruitment and identify strategies to overcome these barriers
- Plan up front for recruitment!!

46

#### Selected References...

- Awidi, M. & Al Hadidi, S. A. (2021). Participation of black Americans in cancer clinical trials: Current challenges and proposed solutions. JCO Oncology Practice, 17(5), 265-271
- Cartmell, K. B., Bonilha, H. S., Simpson, K. N., Ford, M. E., Bryant, D. C., & Alberg, A. J. (2020). Patient barriers to cancer clinical trial participation and navigator activities to assist. *Advances in cancer research*, 146, 139–166.
- Gelinas, L., Pierce, R., Winkler, S., Cohen, I. G., Lunch, H. F., & Bierer, B. E. (2017) Using Social Media as a Research Recruitment Tool: Ethical Issues and Recommendations. *The American Journal of Bioethics*, 17(3), 3-14, doi:10.1080/15265161.2016.1276644

NH) NATIONAL CANCER INSTITU

#### ...Selected References...

- Huang, G. D., Bull, J., McKee, K. J., Mahon, E., Harper, B., & Roberts, J. N. (2018) Contemporary Clinical Trials, 66, 74-79. https://doi.org/10.1016/j.cct.2018.01.003
- Morain, S. R., & Largent, E. A. (2019). Recruitment and Trial-Finding Apps-Time for Rules of the Road. *Journal of* the National Cancer Institute, 111(9), 882–886. https://doi.org/10.1093/jnci/djz076
- Nipp, R. D., Hong, K., & Paskett, E. D. (2019). Overcoming Barriers to Clinical Trial Enrollment. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 39, 105– 114. https://doi.org/10.1200/EDBK\_243729

NIH) NATIONAL CANCER INSTITU

48

## ...Selected References

- Sedrak, M.S., Freedman, R. A., Cohen, H. J., & Muss, H. B. (2021). Older adult participation in cancer clinical trials: A systematic review of barriers and interventions. CA: A Cancer Journal for Clinicians, 71(1), 78-92
- Topolovec-Vranic, J. & Apolinario-Hagen, J. (2016). The Use of Social Media in Recruitment for Medical Research Studies: A Scoping Review. Journal of Medical Internet Research, 18(11), e286. doi:10.2196/jmir.5698
- Unger, J. M., Hershman, D. L., Till, C., Minasian, L. M., Osarogiagbon, R. U., Fleury, M. E., & Vaidya, R. (2021).
   "When Offered to Participate": A Systematic Review and Meta-Analysis of Patient Agreement to Participate in Cancer Clinical Trials. *Journal of the National Cancer Institute*, 113(3), 244–257.

https://doi.org/10.1093/jnci/djaa155



